NASDAQ:CMND Clearmind Medicine Q4 2024 Earnings Report $0.82 -0.03 (-4.00%) As of 09:40 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings History Clearmind Medicine EPS ResultsActual EPS-$44.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AClearmind Medicine Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AClearmind Medicine Announcement DetailsQuarterQ4 2024Date1/22/2025TimeAfter Market ClosesConference Call DateTuesday, January 21, 2025Conference Call Time6:00PM ETConference Call ResourcesReportAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual Report(20-F) Clearmind Medicine Earnings HeadlinesNeuroThera Labs Inc. And Clearmind Medicine Inc. Highlight Enhancement Of U.S. Patent Portfolio Through Collaboration Covering LSD, Ketamine And Ibogaine CombinationsSeptember 23 at 1:43 PM | marketscreener.comMClearmind Medicine Announces U.S. Publication of Patent Applications Covering LSD, Ketamine and Ibogaine Combinations with N-AcylethanolaminesSeptember 23 at 8:11 AM | quiverquant.comQIran War TRUTH: What Two Congressmen Led Me ToTwo private meetings with U.S. Congressmen on March 2nd, three days after the first missiles fell, sent one analyst down an unexpected research trail. The investigation uncovered a coordinated operation, a shadow group running it, and one company sitting at the center of it all.September 24 at 1:00 AM | Behind the Markets (Ad)Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine CombinationsSeptember 23 at 7:57 AM | globenewswire.comClearmind Medicine Testifies at FDA Psychedelic Hearing on Patient Access and MEAI Clinical Trial InsightsSeptember 17, 2026 | quiverquant.comQClearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.September 17, 2026 | globenewswire.comSee More Clearmind Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clearmind Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearmind Medicine and other key companies, straight to your email. Email Address About Clearmind MedicineClearmind Medicine (NASDAQ:CMND) is a biotechnology company focused on developing psychedelic-derived therapeutics for behavioral and mental health disorders. Its research programs are designed to address conditions with significant unmet medical needs, including alcohol use disorder and binge-related behaviors. The company’s pipeline includes investigational compounds based on novel psychedelic molecules, including 5-methoxy-2-aminoindane (MEAI). Clearmind is studying these compounds for their potential to reduce harmful consumption patterns and support improved mental health outcomes. Its activities include preclinical research, drug discovery and the advancement of candidates toward clinical development. Clearmind Medicine is incorporated in Canada and has conducted research and development activities internationally, including in Israel. The company’s programs remain investigational, and its product candidates have not been approved for commercial sale by regulatory authorities.View Clearmind Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
